JAMA Oncology
@JAMAOnc
Followers
49K
Following
389
Media
2K
Statuses
18K
JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
Chicago, IL
Joined September 2014
Absolute neutrophil count–based eligibility criteria in cancer trials disproportionately exclude Black patients with the Duffy null phenotype, suggesting the need for Duffy status–specific thresholds to improve trial equity. https://t.co/3zfb0xfzFK
0
1
7
Can a lower dose of ribociclib help minimize toxic effects in advanced #BreastCancer? A phase 2 clinical trial published in JAMA Oncology provides the latest evidence. Watch the video and read the full results: https://t.co/AlCaU43H7E
0
5
22
From @JAMA_current: The importance of oral health may extend to cancer prevention. New research finds that bacteria and fungi from the mouth may affect pancreatic #cancer risk. #microbiome
https://t.co/vvA3t0S42V
jamanetwork.com
This Medical News article discusses research linking oral bacteria and fungi with pancreatic cancer risk, highlighting microbial signatures that may inform future screening strategies.
1
1
3
In a case-control study of long-term childhood cancer survivors, heart radiation therapy, high-dose anthracyclines, and platinum agents were linked with increased risk of symptomatic valvular heart disease, especially at higher doses and longer follow-up. https://t.co/Kt1BZdsVaC
0
1
10
Breast cancer risk for pathogenic variant carriers is substantially higher with a first-degree family history, and risk estimates vary by gene, family history, and other factors, guiding personalized screening and prevention decisions. https://t.co/4BDRgQWXo3
0
1
9
Specific oral bacteria and fungi were risk factors for pancreatic cancer development, suggesting the potential use of oral microbiota as noninvasive biomarkers for identifying high-risk individuals. https://t.co/vGzQ6U7TgC
0
4
13
In a pooled analysis of patients from 15 phase 3 trials, the risk of #coloncancer recurrence after surgery and adjuvant chemotherapy fell below 0.5% by six years. https://t.co/i6VayFOaPF
1
9
24
A phase 2 trial demonstrated an isotoxic improvement in #cancer control with prostate-specific membrane antigen positron emission tomography-guided intensification of salvage RT after radical prostatectomy. https://t.co/GzaOJLkZUE
1
3
6
A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. https://t.co/ukuuAba0k3
0
2
6
A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. https://t.co/V2qVfR8Crv
1
2
8
Four-year NATALEE trial results show ribociclib plus NSAI maintains invasive disease-free survival benefit over NSAI alone in hormone receptor–positive/ERBB2-negative early breast cancer. https://t.co/pOVpVGEyvU
3
7
24
More young people are now being diagnosed with lung cancer than in the past. This JAMA Oncology Patient Page describes causes, types, and symptoms of lung cancer in people younger than 50 years and how it can be treated. https://t.co/nGkmcqj7iY
0
3
11
A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. https://t.co/2maWeCWfqi
2
12
30
Head and neck cancer is the seventh most common cancer worldwide. This Review provides an overview of EGFR-targeted therapies in HNSCC. https://t.co/jCtg9PJqsb
1
7
40
A prediction model incorporating clonal hematopoiesis and other factors identified substantial heterogeneity in the cancer-preventive effect of low-dose aspirin among older adults. https://t.co/wrTX6oqSZI
0
2
8
Four-year NATALEE trial results show ribociclib plus NSAI maintains invasive disease-free survival benefit over NSAI alone in hormone receptor–positive/ERBB2-negative early breast cancer. https://t.co/6B6GvDWZhZ
3
1
7
Editorial: Comparative efficacy between 400-mg and 600-mg ribociclib doses in hormone receptor–positive breast cancer is clinically minimal, but differences in toxicity are significant. https://t.co/8jTn8oUW5K
3
21
49
Four-year NATALEE trial results show ribociclib plus NSAI maintains invasive disease-free survival benefit over NSAI alone in hormone receptor–positive/ERBB2-negative early breast cancer. https://t.co/M7FpsUk1Qb
3
17
34
A 400-mg ribociclib starting dose did not match the efficacy of 600 mg in HR+/ERBB2− advanced breast cancer, but had similar progression-free survival and fewer adverse events. https://t.co/AXrEBQt3xt
2
25
52
Viewpoint: FDA analysis of primary clinical trial data frequently uncovers risks and flaws not apparent in published studies, highlighting the importance for clinicians to consider these regulatory insights in their treatment decisions. https://t.co/8aGKrU12XQ
1
2
10